Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amonafide in Androgen-Independent Prostate Cancer
NCT00087854Phase 2Completed
- Sponsor
- Xanthus Pharmaceuticals, Inc.
- Start
- Mar 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amonafide in prostate cancer (PCa), sponsored by Xanthus Pharmaceuticals, Inc. Primary endpoints: Safety and Adverse Events and Pharmacokinetic and Pharmacodynamic Profile. Started Mar 2004; status: completed.
02
Drugs
amonafide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00087854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087854.